The global sales of oxytocin are estimated to be worth USD 108.4 million in 2025 and are anticipated to reach a value of USD 245.7 million by 2035. Sales are projected to rise at a CAGR of 8.3% over the forecast period between 2025 and 2035. The revenue generated by oxytocin in 2024 was USD 99.2 million.

Attributes	Key Insights
Historical Size, 2024	USD 99.2 million
Estimated Size, 2025	USD 108.4 million
Projected Size, 2035	USD 245.7 million
Value-based CAGR (2025 to 2035)	8.3%

Semi Annual Market Update

Particular	Value CAGR
H1	9.0% (2024 to 2034)
H2	8.7% (2024 to 2034)
H1	8.3% (2025 to 2035)
H2	7.8% (2025 to 2035)

Country-wise Insights

Countries	Value CAGR (2025 to 2035)
USA	3.1%
Germany	2.7%
UK	6.3%
Spain	4.5%
China	9.2%
India	9.9%

Category-wise Insights

Product Type	Postpartum
Value Share (2025)	87.6%

By Distribution Channel	Hospital Pharmacies
Value Share (2025)	64.5%

The Oxytocin Market Report is Segmented by Indication (Antepartum, Postpartum), Route of Administration (Parenteral, Intranasal, Oromucosal), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

The global oxytocin testing kits market is anticipated to reach USD 1,351.4 million by 2035, rising from USD 740.5 million in 2025 at a 6.2% CAGR.

Attribute	Value
Market Size in 2025	USD 740.5 million
Market Size in 2035	USD 1,351.4 million
CAGR (2025 to 2035)	6.2%

Top Countries Manufacturing, Distributing, and Scaling Oxytocin Testing Kits

Countries	CAGR (2025 to 2035)
United States	5.2%
Germany	5.8%
China	8.9%
Japan	4.4%
India	10.3%

The implementation of an institutional oxytocin checklist did not affect expert assessment of the use of oxytocin in labor. Checklist is included within the publication's appendix.

Abstract: Affectionate touch, which is vital for mental and physical health, was restricted during the Covid-19 pandemic. This study investigated the association between momentary affectionate touch and subjective well-being, as well as salivary oxytocin and cortisol in everyday life during the pandemic. In the first step, we measured anxiety and depression symptoms, loneliness, and attitude toward social touch in a large cross-sectional online survey (N=1,050). From this sample, N=247 participants completed ecologically momentary assessments (EMA) over two days with six daily assessments by answering smartphone-based questions on affectionate touch and momentary mental state and providing concomitant saliva samples for cortisol and oxytocin assessment. Multilevel models showed that on a within-person level, affectionate touch was associated with decreased self-reported anxiety, general burden, stress, and increased oxytocin levels. On a between-person level, affectionate touch was associated with decreased cortisol levels and higher happiness. Moreover, individuals with a positive attitude towards social touch experiencing loneliness reported more mental health problems. Our results suggest that affectionate touch is linked to higher endogenous oxytocin in times of pandemic and lockdown and might buffer stress on a subjective and hormonal level. These findings might have implications for preventing mental burden during social contact restrictions.

Detailed oxytocin protocol in each study.

A collection of 5 brain maps. Each brain map is a 3D array of values representing properties of the brain at different locations.

Collection description

Randomized, double-blind, placebo-controlled, cross-over design to compare the impacts of a single intranasal oxytocin dose on amygdala connectivity among individuals with schizophrenia (n = 22) versus healthy controls (n = 24).

This dataset accompanies the research article "Oxytocin signaling regulates maternally-directed behavior during early life". It includes Matlab data structures for each of the figures in the article. Within each structure are entries for each panel in the figure, including all data points presented in the panel. Panels that do not include any quantitative data (for example images) are also associated with entries in the matlab structures, but these entries are empty.

Main effect of schizophrenia subjects on placebo

Collection description

Randomized, double-blind, placebo-controlled, cross-over design to compare the impacts of a single intranasal oxytocin dose on amygdala connectivity among individuals with schizophrenia (n = 22) versus healthy controls (n = 24).

Subject species

homo sapiens

Modality

fMRI-BOLD

Analysis level

group

Cognitive paradigm (task)

rest eyes closed

Map type

Z

Both oxytocin (OT) and touch are key mediators of social attachment. In rodents, tactile stimulation elicits endogenous release of OT, potentially facilitating attachment and other forms of prosocial behavior, yet the relationship between endogenous OT and neural modulation remains unexplored in humans. Using serial sampling of plasma hormone levels during functional neuroimaging across two successive social interactions, we show that contextual circumstances of social touch influence not only current hormonal and brain responses but also later responses. Namely, touch from a male to his female romantic partner enhanced her subsequent OT release for touch from an unfamiliar stranger, yet females’ OT responses to partner touch were dampened following stranger touch. Hypothalamus and dorsal raphe activation reflected plasma OT changes during the initial social interaction. In the subsequent interaction, precuneus and parietal-temporal cortex pathways tracked time- and context-dependent va...

The table contains 25 products whose active ingredient are classified under the same pharmacologic class Oxytocin [CS].

SPM{T_[416.0]} - contrast 1: G1 > G2

Collection description

The present study assessed the effects of intranasal oxytocin on the neural basis of processing emotional faces in patients with body dysmorphic disorder (BDD). Twenty BDD patients and 22 matched healthy control participants participated in a randomized, double-blind placebo-controlled within-subject functional magnetic resonance imaging study. Following acute intranasal OXT (24 IU) or placebo administration, we examined group and OXT related differences in task-based amygdala activation and related functional connectivity in response to an emotional face-matching task of fearful, angry, disgusted, sad, surprised and happy faces.

Subject species

homo sapiens

Map type

T

Oxytocin infusion regimens.

Social behavior plays an essential role in daily life. The neuropeptide oxytocin has generated considerable interest for its role in social behavior and potential to treat psychiatric disorders characterised by social dysfunction. This study advances our understanding of the neurobiological substrates of social behavior by interrogating human whole-brain maps of oxytocin pathway gene expression, demonstrating these genes are enriched in central, temporal, and olfactory brain regions. We also show via large-scale fMRI meta-analysis that these gene expression patterns correspond with brain regions involved in emotion and motivation processing. These results provide a proof-of-principle demonstration of corresponding mental states with gene expression patterns of a neuropeptide pathway involved in complex human behaviors, and identify neural network targets for future oxytocin trials.

The neurohormone oxytocin regulates many aspects of physiology primarily by binding to its receptor, the oxytocin receptor. The oxytocin receptor gene (Oxtr) has been shown to have alternative transcripts in the mouse brain which may each have different biological functions or be used in specific contexts. A popular animal model for studying oxytocin-dependent social behaviors is the prairie vole, a biparental and monogamous rodent. Alternative transcriptional capacity of Oxtr in prairie voles is unknown. We used 5′ rapid amplification of cDNA ends to identify alternative Oxtr transcription start sites in prairie vole brain tissue and uterine tissue. We then validated expression of specific transcripts in fetal brains and assessed the impact of exogenous oxytocin administration in utero on offspring brain development. We identified seven distinct Oxtr transcripts, all of which are present in both brain and uterine tissue. We then demonstrated that maternal oxytocin administration alters expression of a specific subset of Oxtr transcripts and that these different transcripts are under unique epigenetic regulation, such that in the perinatal period only one of the alternative transcripts is associated with DNA methylation in the Oxtr promoter. These data establish the existence of multiple Oxtr transcripts in prairie vole brain and uterine tissue and implicate oxytocin in the regulation of alternative transcript expression. These data have significant implications for our understanding of null mutant models in both mice and voles and translation in human birth and behavior.

The Oxytocin Market size was valued at USD 4.07 billion in 2023 and is projected to reach USD 8.89 billion by 2032, exhibiting a CAGR of 11.8 % during the forecasts period.

The goal of this study is to determine the prosocial hormone oxytocin (OT) effects on metabolomic profiles in feces.

This study examined oxytocin expression in experimental models of Alzheimer’s disease (AD), and evaluated the therapeutic potential of treatment with oxytocin. They investigated changes in oxytocin expression in APP/PS1 mouse model and developed a chronic intranasal treatment protocol to increase oxytocin levels in the brain. Then, tested oxytocin as a potential approach to attenuate microglial activation and reverse memory deficits. This dataset includes source data used to assemble different figures in the publication. The source data contains data about hypothalamic expression of oxytocin is reduced in AD models, chronic intranasal administration of oxytocin increases hippocampal oxytocin and attenuates fear response in mice, cellular and molecular impact of intranasal oxytocin in APP/PS1 mouse brains, oxytocin attenuates AβO-induced microglial activation in vitro, and intranasal oxytocin reverses social and non-social memory deficits in aged APP/PS1 mice.

The table includes 76 products with the active ingredient Oxytocin.

Introduction: In recent years, several studies were conducted to explore the potential augmenting effect of oxytocin for the treatment of individuals with severe mental illness. Nonetheless, studies exploring its effects in routine inpatient settings using high-quality randomized controlled trials are scarce. The current study assessed the effect of oxytocin administration on treatment process and outcome among psychiatric inpatients, while employing a rigorous experimental methodology. Methods: A double-blind, placebo-controlled, randomized trial was conducted at a public psychiatric hospital in Israel. Patients (N = 87, 71.3% female participants) were administered intranasal oxytocin/placebo twice daily for 4 weeks, as add-on to usual care. Patients were assessed for severity of anxiety and depression symptoms and their working alliance with their therapist after each therapy session, and treatment outcome was assessed weekly. Multilevel modeling was performed to assess the linear change from pre- to post-treatment. Results: Patients receiving OT demonstrated significantly larger symptomatic improvements (B = −0.01, t [437] = −2.36, p = 0.01). Larger gains were also observed for depression (B = −0.14, p < 0.001 in the OT group, B = −0.06, p = 0.02 in the placebo group) and general distress (B = −0.57, p < 0.001 in the OT group, B = −0.29, p = 0.02 in the placebo group). No significant effect was observed for anxiety, the working alliance, or attachment. Discussion: Oxytocin has the potential to improve treatment outcome among inpatients. Nonetheless, additional controlled research is needed to further assess its effects on therapy process, as well as to account for therapeutic, pharmacological, and neuronal intervening factors.